The FDA has approved the first generic versions of Fosamax (alendronate sodium tablets), used to treat osteoporosis. Osteoporos is a condition that causes thinning and weakening of bones and is often one of the many significant side effects from Hormone Therapy. Teva Pharmaceuticals USA has received approval to manufacture alendronate sodium tablets in three once-daily [...]
According to a recent presentation by Mitchell C. Benson, MD*, at the 32nd Winter Urologic Forum - State-of-the-Art in Urology - January 25-29, 2008 - Vail, Colorado, USA most men who have failed a local, primary therapy and then experience a rising PSA will find that their follow-up therapy will most probably consist of anti-androgen [...]
The normal protocol when chemotherapy is administered to men who have androgen-independent prostate cancer (AIPC) is to continue the androgen deprivation program despite its failure to any longer suppress the cancer’s growth. A study published by the Department of Medical Oncology, St Bartholomew's Hospital, London, UK, examined whether it was possible to re-induce hormone sensitivity [...]
There are many advocates of adding Avodart (dutasteride) or Proscar (finasteride) to a hormone blockade. On the flip side, there are also many who are against adding these drugs. Why are many oncologists reluctant to prescribe Avodart or Proscar? Answer: The apparent reluctance is related to the lack of evidence that these medications are beneficial [...]
According to an article published today at UroToday.com, a pituitary apoplexy or sudden neurological impairment characterized by headache, visual deficits, altered mental status, and nausea, can occur after administration of a gonadotropin-releasing hormone agonist (GnRHa), or a hormone blockade. A pituitary apoplexy is rare and is generally thought to be due to hemorrhage or infarction [...]